eFFECTOR Therapeutics, Inc.
11180 Roselle Street
Suite A
San Diego
California
92121
United States
About eFFECTOR Therapeutics, Inc.
82 articles about eFFECTOR Therapeutics, Inc.
-
eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference
6/7/2022
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at JMP Securities Life Sciences Conference.
-
eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity
6/5/2022
eFFECTOR Therapeutics, Inc. reported positive interim results of the company’s ongoing Phase 1/2 clinical trial of eIF4A inhibitor zotatifin in patients with solid tumors that showed treatment was generally well tolerated, resulted in suppression of multiple oncogenic drivers and demonstrated initial signals of clinical activity.
-
eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting
5/26/2022
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that it will present interim data from its ongoing Phase 1/2 dose escalation and expansion trial of zotatifin in multiple solid tumors in an oral poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/10/2022
eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, reported financial results for the first quarter ended March 31, 2022, and provided a corporate update.
-
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences - May 02, 2022
5/2/2022
eFFECTOR Therapeutics, Inc. announced that the management team will participate in and host 1x1 meetings at the following upcoming investor conferences:
-
BioSpace Movers & Shakers, April 8
4/8/2022
Onxeo, Amydis, eFFECTOR Therapeutics, Freenome, Urovant Sciences and others all added new guidance and perspectives to their C-suite this week. -
eFFECTOR Therapeutics Announces Transition in Clinical Leadership
4/4/2022
eFFECTOR Therapeutics, Inc. today announced that its chief medical officer Premal Patel, M.D., Ph.D., has resigned to pursue a new opportunity. Robert Sikorski, M.D., Ph.D., who currently serves as a clinical advisor to the company, will take on an expanded role as senior clinical development advisor while the company conducts an executive search for a new chief medical officer.
-
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/16/2022
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update.
-
BioSpace Movers & Shakers, Feb. 18
2/18/2022
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
eFFECTOR Appoints Kristen Harrington-Smith to Board of Directors
2/16/2022
eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the appointment of Kristen Harrington-Smith, Senior Vice President & Chief Commercial Officer at ImmunoGen, to the company’s board of directors.
-
eFFECTOR Therapeutics to Present at 2022 BIO CEO & Investor Conference
2/9/2022
eFFECTOR Therapeutics, a biopharmaceutical company focused on pioneering the development of selective translation regulator inhibitors for the treatment of cancer, announced that the Company will present and host 1x1 meetings at the 2022 BIO CEO & Investor Conference.
-
eFFECTOR Therapeutics Provides Pipeline and Business Updates
1/24/2022
eFFECTOR Therapeutics, Inc. today announced multiple pipeline updates for its ongoing development programs.
-
eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology
11/24/2021
eFFECTOR Therapeutics, Inc. announced today the publication of data highlighting the anti-tumor potential of zotatifin, the company’s clinical-stage inhibitor of eukaryotic translation initiation factor 4A .
-
eFFECTOR Therapeutics to Participate in The JMP Securities Hematology and Oncology Summit
11/22/2021
eFFECTOR Therapeutics (NASDAQ: EFTR), today announced that Steve Worland, Ph.D., President and Chief Executive Officer of eFFECTOR, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Monday, December 6 at 3:20 p.m. ET.
-
eFFECTOR Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11/8/2021
eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
-
eFFECTOR Appoints Barbara Klencke, M.D., to Board of Directors
11/1/2021
eFFECTOR Therapeutics, a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced the appointment of Barbara Klencke, M.D., Chief Medical Officer and Chief Development Officer at Sierra Oncology, to the company’s board of directors.
-
Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development of Zotatifin in Triple-Negative Breast Cancer at 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/7/2021
eFFECTOR Therapeutics, a leader in the development of selective translation regulator inhibitors for the treatment of cancer, in collaboration with investigators at Baylor College of Medicine, announced the presentation of new positive data for zotatifin in animal models of triple-negative breast cancer at the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
-
Baylor College of Medicine to Present eFFECTOR Therapeutics-Supported Research at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9/30/2021
eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that eFFECTOR-supported research from Baylor College of Medicine entitled, “The RNA helicase EIF4A is a therapeutic vulnerability in triple-negative breast cancer” has been accepted as a poster presentation at the upcoming 2021 AACR-NCI-EORTC International Conference.
-
eFFECTOR Therapeutics to Participate in 2021 Cantor Virtual Healthcare Conference
9/16/2021
eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that company management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference.
-
eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies
8/25/2021
eFFECTOR Therapeutics, Inc. (eFFECTOR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today completed its business combination with Locust Walk Acquisition Corp. (NASDAQ: LWAC).